Based on the Transgene SA stock forecast from 0 analysts, the average analyst target price for Transgene SA is not available over the next 12 months. Transgene SA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Transgene SA is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Transgene SA’s stock price was USD 1.59. Transgene SA’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -1.85% over the last year.
No recent analyst target price found for Transgene SA
No recent average analyst rating found for Transgene SA
Company Overview Transgene SA
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of gastrointestinal and colorectal cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of hepatitis B; TG6050 for the treatment of non-small cell lung cancer, and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Merck & Co, Sanofi, BioInvent, and Randox. Transgene SA was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS. Read Less
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase I clinical trial for the treatment of ovarian canc...Read More
Frequently Asked Questions About Transgene SA (TRGNF) Stock
Stock Target Advisor's fundamental analysis for Transgene SA's stock is Bearish.
Unfortunately we do not have enough data on TRGNF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TRGNF's stock to indicate what its average analyst target is.
TRGNF stock's Price/Earning ratio is 14.33.
Our analysis grades TRGNF stock's Price / Earning ratio at F. This means that TRGNF stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this TRGNF may be a overvalued for its sector.
The last closing price of TRGNF's stock was USD 1.59.
The most recent market capitalization for TRGNF is USD 0.21B.
Unfortunately we do not have enough analyst data on TRGNF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Transgene SA's stock.
As per our most recent records Transgene SA has 146 Employees.
Transgene SA's registered address is 400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405.
You can get more information about it from Transgene SA's website at https://www.transgene.fr.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Transgene SA (TRGNF) Stock
Stock Target Advisor's fundamental analysis for Transgene SA's stock is Bearish.
Unfortunately we do not have enough data on TRGNF's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on TRGNF's stock to indicate what its average analyst target is.
TRGNF stock's Price/Earning ratio is 14.33.
Our analysis grades TRGNF stock's Price / Earning ratio at F. This means that TRGNF stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the OTC exchange.
Based on this TRGNF may be a overvalued for its sector.
The last closing price of TRGNF's stock was USD 1.59.
The most recent market capitalization for TRGNF is USD 0.21B.
Unfortunately we do not have enough analyst data on TRGNF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Transgene SA's stock.
As per our most recent records Transgene SA has 146 Employees.
Transgene SA's registered address is 400, boulevard Gonthier d?Andernach, Illkirch-Graffenstaden, France, 67405.
You can get more information about it from Transgene SA's website at https://www.transgene.fr.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TRGNF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
